Loss to follow-up in an international, multicentre observational study

被引:82
作者
Mocroft, A. [1 ]
Kirk, O. [2 ]
Aldins, P. [3 ]
Chies, A. [4 ]
Blaxhult, A. [5 ]
Chentsova, N. [6 ]
Vetter, N. [7 ]
Dabis, F. [8 ]
Gatell, J. [9 ]
Lundgren, J. D. [2 ]
机构
[1] UCL Royal Free & Univ Coll Med Sch, Royal Free Ctr HIV Med, London NW3 2PF, England
[2] Univ Copenhagen, Panum Inst, Copenhagen HIV Programme, DK-2200 Copenhagen, Denmark
[3] Infectol Ctr Lativa, Riga, Latvia
[4] Ist Super Sanita, I-00161 Rome, Italy
[5] Swedish Inst Infect Dis, Solna, Sweden
[6] Kyiv Ctr AIDS, Kiev, Ukraine
[7] Pulmol Zentrum Stadt Wien, Vienna, Austria
[8] Univ Victor Segalen, INSERM, ISPED, Unite 593, Bordeaux, France
[9] Hosp Clin Barcelona, Barcelona, Spain
关键词
loss to follow-up; survival; vital status;
D O I
10.1111/j.1468-1293.2008.00557.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective The aim of this work was to assess loss to follow-up (LTFU) in EuroSIDA, an international multicentre observational cohort study. Methods LTFU was defined as no follow-up visit, CD4 cell count measurement or viral load measurement after 1 January 2006. Poisson regression was used to describe factors related to LTFU. Results The incidence of LTFU in 12 304 patients was 3.72 per 100 person-years of follow-up [95% confidence interval (CI) 3.58-3.86; 2712 LTFU] and varied among countries from 0.67 to 13.35. After adjustment, older patients, those with higher CD4 cell counts, and those who had started combination antiretroviral therapy all had lower incidences of LTFU, while injecting drug users had a higher incidence of LTFU. Compared with patients from Southern Europe and Argentina, patients from Eastern Europe had over a twofold increased incidence of LTFU after adjustment (incidence rate ratio 2.16; 95% CI 1.84-2.53; P < 0.0001). A total of 2743 patients had a period of > 1 year with no CD4 cell count or viral load measured during the year; 743 (27.1%) subsequently returned to follow-up. Conclusions Some patients thought to be LTFU may have died, and efforts should be made to ascertain vital status wherever possible. A significant proportion of patients who have a year with no follow-up visit, CD4 cell count measurement or viral load measurement subsequently return to follow-up.
引用
收藏
页码:261 / 269
页数:9
相关论文
共 16 条
[1]   Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from sub-Saharan Africa [J].
Anglaret, X ;
Toure, S ;
Gourvellec, G ;
Tchehy, A ;
Zio, L ;
Zaho, M ;
Kassi, MC ;
Lehou, J ;
Coulibaly, H ;
Seyler, C ;
N'Dri-Yoman, T ;
Salamon, R ;
Chêne, G .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 35 (03) :320-323
[2]  
Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2
[3]   A national HIV community cohort: Design, baseline, and follow-up of the AmFAR observational database [J].
Cohen, CJ ;
Iwane, MK ;
Palensky, JB ;
Levin, DL ;
Meagher, KJ ;
Frost, KR ;
Mayer, KH .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (09) :779-793
[4]   Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study [J].
Egger, M ;
Hirschel, B ;
Francioli, P ;
Sudre, P ;
Wirz, M ;
Flepp, M ;
Rickenbach, M ;
Malinverni, R ;
Vernazza, P ;
Battegay, M ;
Bernasconi, E ;
Burgisser, P ;
Erb, P ;
Fierz, W ;
Grob, P ;
Gruninger, U ;
Jeannerod, L ;
Ledergerber, B ;
Luthy, R ;
Matter, L ;
Opravil, M ;
Paccaud, F ;
Perrin, L ;
Pichler, W ;
Piffaretti, GC ;
Rutschmann, O ;
Zanetti, G .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7117) :1194-1199
[5]  
El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360
[6]   The Evaluation of Subcutaneous Proleukin® (interleukin-2) in a Randomized International Trial:: rationale, design, and methods of ESPRIT [J].
Emery, S ;
Abrams, DI ;
Cooper, DA ;
Darbyshire, JH ;
Lane, HC ;
Lundgren, JD ;
Neaton, JD .
CONTROLLED CLINICAL TRIALS, 2002, 23 (02) :198-220
[7]   Participation in research and access to experimental treatments by HIV-infected patients [J].
Gifford, AL ;
Cunningham, WE ;
Heslin, KC ;
Andersen, RM ;
Nakazono, T ;
Lieu, DK ;
Shapiro, MF ;
Bozzette, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (18) :1373-1382
[8]   Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya [J].
Karcher, Heiko ;
Omondi, Austin ;
Odera, John ;
Kunz, Andrea ;
Harms, Gundel .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2007, 12 (05) :687-694
[9]  
LANOY E, WHAT HAPPENS PATIENT
[10]   Interval and clinical cohort studies: Epidemiological issues [J].
Lau, Bryan ;
Gange, Stephen J. ;
Moore, Richard D. .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (06) :769-776